Inter-tumor and inter-model heterogeneity of trastuzumab distribution is also illustrated in Fig. 5c with examples of MDA-MB-361, JIMT-1 and BT474 breast cancers and SKOV3 ovarian carcinoma, all showing significant areas of HER2-positive tissue without bound trastuzumab. Here, ERBB2 is linked to ovarian carcinoma.